María José
Larráyoz Ilundáin
Clínico Asociado
Hospital Universitario La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (12)
2024
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2022
2021
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
2020
-
Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide
British Journal of Haematology
-
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
British Journal of Haematology
2015
-
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations
British Journal of Haematology
2014
-
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
Leukemia, Vol. 28, Núm. 4, pp. 823-829
2013
-
Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations
British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86
-
Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing
Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177
2011
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2009
-
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis
Journal of Molecular Diagnostics, Vol. 11, Núm. 5, pp. 458-463